Eli Lilly's Mixed Q4 Results
This is a U.S. news story, published by CNBC, that relates primarily to Zepbound news.
U.S. news
For more U.S. news, you can click here:
more U.S. newsZepbound news
For more Zepbound news, you can click here:
more Zepbound newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsCNBC news
For more news from CNBC, you can click here:
more news from CNBCAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
preliminary results Eli Lilly. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest revenue guidance news, quarter revenue news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
blockbuster weight loss ZepboundCNBC
•Health
Health
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

77% Informative
Demand in the U.S. has far outpaced supply for Eli Lilly’s incretin drugs, such as Zepbound and Mounjaro , over the last year .
The pharmaceutical giant also issued fiscal 2025 profit guidance of $ 22.05 to $ 23.55 per share, which is in line with what analysts were expecting.
VR Score
88
Informative language
95
Neutral language
41
Article tone
formal
Language
English
Language complexity
41
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links